Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Sells ProteinChip Systems to Japanese Drug Discovery Proteome Project

NEW YORK, April 19 (GenomeWeb News) - Ciphergen Biosystems announced today that its Japanese subsidiary has been named one of the official technology suppliers of the Japanese Drug Discovery Proteome Factory project.


Ciphergen has so far sold to the project three ProteinChip AutoBiomarker Systems and two ProteinChip interfaces for use with tandem mass spec.


The five-year Japanese project, which began in 2002, involves 20 Japanese pharma companies and is funded by the Japan Health Science Foundation to the tune of 4.5 billion yen ($41 million). The goal of the project is to gain information on proteins involved in cancer, diabetes, hypertension, asthma, and dementia.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.